Silence Therapeutics plc

Regulatory Filings • Feb 20, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3199F

Silence Therapeutics PLC

20 February 2018

Silence Therapeutics Notice of Results

London, 20th February 2018

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce its Preliminary Results for the twelve months ended 31st December, 2017 on Tuesday 6th March 2018.

Ali Mortazavi, Chief Executive Officer and David Ellam, Chief Financial Officer, will host a presentation for analysts at 9:00am on the day of the results at the Devonshire Club, 5 Devonshire Square, London EC2M 4YD.

Enquiries:

Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer	Tel:  +44 (0)20 3457 6900
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson	Tel:  +44 (0)20 7418 8900
Media Enquiries: Optimum Strategic Communications  Mary Clark/ Eva Haas/Hollie Vile [email protected]	Tel: +44 (0) 20 3714 17

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORZMGMZNLVGRZM